Liu Yang, Bian Weishuai, Liu Ping, Zang Xuefeng, Gu Xuyun, Chen Wei
Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Interact Cardiovasc Thorac Surg. 2018 May 1;26(5):852-858. doi: 10.1093/icvts/ivy043.
Dexmedetomidine has been shown to decrease cardiac complications in adults undergoing cardiac surgery. Results from clinical trials of dexmedetomidine on outcomes following paediatric cardiac surgery are controversial.
We searched EMBASE, PubMed and Cochrane CENTRAL databases for randomized controlled trials comparing the effect of dexmedetomidine versus placebo or other anaesthetic drugs in paediatric patients undergoing cardiac surgery. The primary outcome was the duration of mechanical ventilation. The secondary outcomes were intensive care unit stay, hospital length of stay (LOS), incidence of junctional ectopic tachycardia and postoperative deaths.
Nine trials with a total of 837 patients were selected. Compared with controls, dexmedetomidine significantly reduced the postoperative duration of mechanical ventilation [in hours; n = 837; weighted mean difference -2.20, 95% confidence interval (CI) -3.51 to -0.90; P = 0.001; I2 = 97%], intensive care unit LOS (in days; n = 737; weighted mean difference -0.47, 95% CI -0.90 to -0.03; P = 0.03; I2 = 97%) and hospital LOS (in days; n = 291; weighted mean difference -1.80, 95% CI -3.36 to -0.25; P = 0.02; I2 = 96%). Dexmedetomidine also significantly reduced the incidence of postoperative junctional ectopic tachycardia (21/292 vs 50/263; risk ratio 0.40, 95% CI 0.25-0.64; P = 0.0001; I2 = 0.0%), but there was no difference between groups in postoperative deaths (4/182 vs 6/153; odds ratio 0.54, 95% CI 0.15-1.93; P = 0.34; I2 = 0.0%).
Perioperative administration of dexmedetomidine to paediatric patients undergoing cardiac surgery may shorten the duration of mechanical ventilation, LOS in the intensive care unit and in the hospital and reduce the incidence of junctional ectopic tachycardia. More high-quality randomized controlled trials are encouraged to verify the beneficial effect of dexmedetomidine before its clinical application in paediatric patients undergoing surgery for congenital heart disease.
右美托咪定已被证明可降低接受心脏手术的成人的心脏并发症。右美托咪定对小儿心脏手术后结局影响的临床试验结果存在争议。
我们检索了EMBASE、PubMed和Cochrane CENTRAL数据库,以查找比较右美托咪定与安慰剂或其他麻醉药物对接受心脏手术的小儿患者效果的随机对照试验。主要结局是机械通气时间。次要结局包括重症监护病房住院时间、住院时间、交界性异位性心动过速发生率和术后死亡。
共入选9项试验,总计837例患者。与对照组相比,右美托咪定显著缩短了术后机械通气时间[小时;n = 837;加权平均差-2.20,95%置信区间(CI)-3.51至-0.90;P = 0.001;I² = 97%]、重症监护病房住院时间(天;n = 737;加权平均差-0.47,95% CI -0.90至-0.03;P = 0.03;I² = 97%)和住院时间(天;n = 291;加权平均差-1.80,95% CI -3.36至-0.25;P = 0.02;I² = 96%)。右美托咪定还显著降低了术后交界性异位性心动过速的发生率(21/292 vs 50/263;风险比0.40,95% CI 0.25 - 0.64;P = 0.0001;I² = 0.0%),但两组术后死亡无差异(4/182 vs 6/153;比值比0.54,95% CI 0.15 - 1.93;P = 0.34;I² = 0.0%)。
对接受心脏手术的小儿患者围手术期给予右美托咪定可能会缩短机械通气时间、重症监护病房和医院住院时间,并降低交界性异位性心动过速的发生率。在右美托咪定临床应用于先天性心脏病手术小儿患者之前,鼓励开展更多高质量随机对照试验以验证其有益效果。